Eli Lilly to present baricitinib data at ARHP Annual Meeting

Eli Lilly and Co.'s analysis of its Phase 3 baricitinib trial efficiency and safety data, as well as that of other Phase 2 trials, will be presented at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting, which is being held on Nov. 11-16 in Washington, D.C.
"The positive data to be presented at ACR provide further support for baricitinib as a potential treatment option for rheumatoid arthritis patients," Eli Lilly Senior Vice President of Product Development Dr. J. Anthony Ware said. "We look forward to presenting these new results, along with other important data from our immunology portfolio, as we continue our work to address and alleviate unmet needs people living with chronic autoimmune diseases face."
Eli Lilly has stated that six abstracts, one of which will be an oral presentation, will discuss the data and results from the Phase 3 Taltz trial. This trial assessed the ability of Taltz to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis.